Choosing among second-generation antidepressant treatments for depressed patients with cardiac diseases

References

• Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., … Beasley, C. (1999). Blood pressure changes during short-term fluoxetine treatment. Journal of Clinical Psychopharmacology, 19, 9–14. doi:10.1097/00004714-199902000-00004
   PubMed Web of Science ®Google Scholar
• An, L., Ravindran, P. P., Renukunta, S., & Denduluri, S. (2013). Co-medication of pravastatin and paroxetine-a categorical study. Journal of Clinical Pharmacology, 53, 1212–1219. doi:10.1002/jcph.151
   PubMed Web of Science ®Google Scholar
• Azaz-Livshits, T. L. & Danenberg, H. D. (1997). Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry, 30, 274–275. doi:10.1055/s-2007-979508
   PubMed Web of Science ®Google Scholar
• Baker, B., Dorian, P., Sandor, P., Shapiro, C., Schell, C., Mitchell, J., … Irvine, M. J. (1997). Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. Journal of Clinical Psychopharmacology, 17, 15–21 doi:10.1097/00004714-199702000-00004
   PubMed Web of Science ®Google Scholar
• Bauer, M., Severus, E., Kohler, S., Whybrow, P. C., Angst, J., & Moller, H. J. (2015). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: Maintenance treatment of major depressive disorder-update 2015. World Journal of Biological Psychiatry, 16, 76–95. doi:10.3109/15622975.2014.1001786
   PubMed Web of Science ®Google Scholar
• Bavle, A. D. & Phatak, A. S. (2013). Bupropion-warfarin combination: A serious complication. Indian Journal of Psychological Medicine, 35, 311–313. doi:10.4103/0253-7176.119488
   PubMedGoogle Scholar
• Benfield, P. & Ward, A. (1986). Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs, 32, 313–334. doi:10.2165/00003495-198632040-00002
   PubMed Web of Science ®Google Scholar
• Briciu, C., Neag, M., Muntean, D., Vlase, L., Bocsan, C., Buzoianu, A., … Popa, A. (2014). A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. Journal of Clinical Pharmacy and Therapeutics, 39, 535–540. doi:10.1111/jcpt.12180
   PubMed Web of Science ®Google Scholar
• Brosen, K. & Naranjo, C. A. (2001). Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. European Neuropsychopharmacology, 11, 275–283. doi:10.1016/S0924-977X(01)00101-8
   PubMed Web of Science ®Google Scholar
• Carney, R. M. & Freedland, K. E. (2017). Depression and coronary heart disease. Nature Reviews Cardiology, 14, 145–155. doi:10.1038/nrcardio.2016.181
   PubMed Web of Science ®Google Scholar
• Castro, V. M., Clements, C. C., Murphy, S. N., Gainer, V. S., Fava, M., Weilburg, J. B., … Perlis, R. H. (2013). QT interval and antidepressant use: A cross sectional study of electronic health records. British Medical Journal, 346, f288. doi:10.1136/bmj.f288
   PubMed Web of Science ®Google Scholar
• Chang, C. C., Tzeng, N. S., Yeh, C. B., Kuo, T. B. J., Huang, S. Y., & Chang, H. A. (2017). Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk. The World Journal of Biological Psychiatry, 1–11.
   PubMed Web of Science ®Google Scholar
• Chappell, J., He, J., Knadler, M. P., Mitchell, M., Lee, D., & Lobo, E. (2009). Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. Journal of Clinical Pharmacology, 49, 1456–1466. doi:10.1177/0091270009344335
   PubMed Web of Science ®Google Scholar
• Chen, G., Zhang, W., & Serenko, M. (2015). Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. Journal of Clinical Pharmacology, 55, 671–679. doi:10.1002/jcph.456
   PubMed Web of Science ®Google Scholar
• Cohen, H. W., Gibson, G., & Alderman, M. H. (2000). Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents. The American Journal of Medicine, 108, 2–8. doi:10.1016/S0002-9343(99)00301-0
   PubMed Web of Science ®Google Scholar
• Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., & Hippisley-Cox, J. (2011). Antidepressant use and risk of adverse outcomes in older people: Population based cohort study. British Medical Journal, 343, d4551. doi:10.1136/bmj.d4551
   PubMed Web of Science ®Google Scholar
• Coupland, C., Hill, T., Morriss, R., Moore, M., Arthur, A., & Hippisley-Cox, J. (2016). Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: Cohort study using primary care database. British Medical Journal, 352, i1350.
   PubMedGoogle Scholar
• Cupp, M. J. & Tracy, T. S. (1998). Cytochrome P450: New nomenclature and clinical implications. American Family Physician, 57, 107–116.
   PubMed Web of Science ®Google Scholar
• Davidson, K. W. (2012). Depression and coronary heart disease. International Scholarly Research Notices Cardiology, 2012, 743813. doi:10.5402/2012/743813
   Google Scholar
• de Abajo, F. J. (2011). Effects of selective serotonin reuptake inhibitors on platelet function: Mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging, 28, 345–367. doi:10.2165/11589340-000000000-00000
   PubMed Web of Science ®Google Scholar
• de Boer, R. A., van Dijk, T. H., Holman, N. D., & van Melle, J. P. (2005). QT interval prolongation after sertraline overdose: A case report. BMC Emergency Medicine, 5, 5. doi:10.1186/1471-227X-5-5
   PubMedGoogle Scholar
• de Jonge, P., Spijkerman, T. A., van den Brink, R. H., & Ormel, J. (2006). Depression after myocardial infarction is a risk factor for declining health related quality of life and increased disability and cardiac complaints at 12 months. Heart, 92, 32–39. doi:10.1136/hrt.2004.059451
   PubMed Web of Science ®Google Scholar
• Delavenne, X., Magnin, M., Basset, T., Piot, M., Mallouk, N., Ressnikoff, D., … Mismetti, P. (2013). Investigation of drug-drug interactions between clopidogrel and fluoxetine. Fundamental & Clinical Pharmacology, 27, 683–689. doi:10.1111/fcp.12021
   PubMed Web of Science ®Google Scholar
• Dent, L. A. & Orrock, M. W. (1997). Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy, 17, 170–172.
   PubMed Web of Science ®Google Scholar
• Dezsi, C. A. & Szentes, V. (2017). The real role of beta-blockers in daily cardiovascular therapy. American Journal of Cardiovascular Drugs, 17, 361–373. doi:10.1007/s40256-017-0221-8
   PubMed Web of Science ®Google Scholar
• Diaper, A., Rich, A. S., Wilson, S. J., Craig, K., Dourish, C. T., Dawson, G. R., … Bailey, J. E. (2013). Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Human Psychopharmacology, 28, 562–575. doi:10.1002/hup.2346
   PubMed Web of Science ®Google Scholar
• Dold, M. & Kasper, S. (2017). Evidence-based pharmacotherapy of treatment-resistant unipolar depression. International Journal of Psychiatry in Clinical Practice, 21, 13–23. doi:10.1080/13651501.2016.1248852
   PubMed Web of Science ®Google Scholar
• Donazzolo, Y., Latreille, M., Caillaud, M. A., Mocaer, E., & Seguin, L. (2014). Evaluation of the effects of therapeutic and supratherapeutic doses of agomelatine on the QT/QTc interval: A phase I, randomized, double-blind, placebo-controlled and positive-controlled, crossover thorough QT/QTc study conducted in healthy volunteers. Journal of Cardiovascular Pharmacology, 64, 440–451. doi:10.1097/FJC.0000000000000136
   PubMed Web of Science ®Google Scholar
• Druteika, D. & Zed, P. J. (2002). Cardiotoxicity following bupropion overdose. The Annals of Pharmacotherapy, 36, 1791–1795. doi:10.1345/aph.1C045
   PubMed Web of Science ®Google Scholar
• Egede, L. E. (2007). Major depression in individuals with chronic medical disorders: Prevalence, correlates and association with health resource utilization, lost productivity and functional disability. General Hospital Psychiatry, 29, 409–416. doi:10.1016/j.genhosppsych.2007.06.002
   PubMed Web of Science ®Google Scholar
• Ellison, J. M., Milofsky, J. E., & Ely, E. (1990). Fluoxetine-induced bradycardia and syncope in two patients. The Journal of Clinical Psychiatry, 51, 385–386.
   PubMed Web of Science ®Google Scholar
• Fayssoil, A., Issi, J., Guerbaa, M., Raynaud, J. C., & Heroguelle, V. (2011). Torsade de pointes induced by citalopram and amiodarone. Annales De Cardiologie Et D Angeiologie, 60, 165–168. doi:10.1016/j.ancard.2010.12.002
   PubMed Web of Science ®Google Scholar
• Franco, V. (2015). Wide complex tachycardia after bupropion overdose. The American Journal of Emergency Medicine, 33, 1540–1545. doi:S0735-6757(15)00619-1
   PubMed Web of Science ®Google Scholar
• Frasure-Smith, N., Lesperance, F., Gravel, G., Masson, A., Juneau, M., Talajic, M., & Bourassa, M. G. (2000). Depression and health-care costs during the first year following myocardial infarction. The Journal of Psychosomatic Research, 48, 471–478. doi:10.1016/S0022-3999(99)00088-4
   PubMed Web of Science ®Google Scholar
• Frasure-Smith, N., Lesperance, F., & Talajic, M. (1993). Depression following myocardial infarction. Impact on 6-month survival. The Journal of the American Medical Association, 270, 1819–1825. doi:10.1001/jama.1993.03510150053029
   PubMed Web of Science ®Google Scholar
• Gelenberg, A. J., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H. et al. (2010). Practice guideline for the treatment of patients with major depressive disorder. (3rd ed.). Washington, DC: American Psychiatric Association.
   Google Scholar
• Ghanizadeh, A. & Hedayati, A. (2013). Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depression and Anxiety, 30, 1084–1088. doi:10.1002/da.22195
   PubMed Web of Science ®Google Scholar
• Gheldiu, A. M., Popa, A., Neag, M., Muntean, D., Bocsan, C., Buzoianu, A., … Briciu, C. (2016). Assessment of a potential pharmacokinetic interaction between nebivolol and bupropion in healthy volunteers. Pharmacology, 98, 190–198. doi:10.1159/000447266
   PubMed Web of Science ®Google Scholar
• Gheldiu, A. M., Vlase, L., Popa, A., Briciu, C., Muntean, D., Bocsan, C., … Neag, M. (2017). Investigation of a potential pharmacokinetic interaction between nebivolol and fluvoxamine in healthy volunteers. Journal of Pharmacy and Pharmaceutical Sciences, 20, 68–80. doi:10.18433/J3B61H
   PubMed Web of Science ®Google Scholar
• Girardin, F. R., Gex-Fabry, M., Berney, P., Shah, D., Gaspoz, J. M., & Dayer, P. (2013). Drug-induced long QT in adult psychiatric inpatients: The 5-year cross-sectional ECG screening outcome in psychiatry study. The American Journal of Psychiatry, 170, 1468–1476. doi:10.1176/appi.ajp.2013.12060860
   PubMed Web of Science ®Google Scholar
• Glassman, A. H., O'Connor, C. M., Califf, R. M., Swedberg, K., Schwartz, P., Bigger, J. T., Jr., … Mclvor, M. (2002). Sertraline treatment of major depression in patients with acute MI or unstable angina. The Journal of the American Medical Association, 288, 701–709. doi:10.1001/jama.288.6.701
   PubMed Web of Science ®Google Scholar
• Goldstein, C. M., Gathright, E. C., & Garcia, S. (2017). Relationship between depression and medication adherence in cardiovascular disease: the perfect challenge for the integrated care team. Patient Preference and Adherence, 11, 547–559. doi:10.2147/PPA.S127277
   PubMed Web of Science ®Google Scholar
• Goryachkina, K., Burbello, A., Boldueva, S., Babak, S., Bergman, U., & Bertilsson, L. (2008). Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). The European Journal of Clinical Pharmacology, 64, 275–282. doi:10.1007/s00228-007-0404-3
   PubMed Web of Science ®Google Scholar
• Gougol, A., Zareh-Mohammadi, N., Raheb, S., Farokhnia, M., Salimi, S., Iranpour, N., … Akhondzadeh, S. (2015). Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. Journal of Psychopharmacology, 29, 575–581. doi:10.1177/0269881115578160
   PubMed Web of Science ®Google Scholar
• Graff, D. W., Williamson, K. M., Pieper, J. A., Carson, S. W., Adams, K. F., Jr., Cascio, W. E., … Patterson, J. H. (2001). Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. Journal of Clinical Pharmacology, 41, 97–106. doi:10.1177/00912700122009746
   PubMed Web of Science ®Google Scholar
• Hanash, J. A., Hansen, B. H., Hansen, J. F., Nielsen, O. W., Rasmussen, A., & Birket-Smith, M. (2012). Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: Results from the depression in patients with Coronary Artery Disease (DECARD) trial. Journal of Cardiovascular Pharmacology, 60, 397–405. doi:10.1097/FJC.0b013e3182677041
   PubMed Web of Science ®Google Scholar
• Hansen, R. A., Khodneva, Y., Glasser, S. P., Qian, J., Redmond, N., & Safford, M. M. (2016). Antidepressant medication use and its association with cardiovascular disease and all-cause mortality in the reasons for geographic and racial differences in stroke (REGARDS) study. The Annals of Pharmacotherapy, 50, 253–261. doi:10.1177/1060028015625284
   PubMed Web of Science ®Google Scholar
• Hemeryck, A., Lefebvre, R. A., De, V. C., & Belpaire, F. M. (2000). Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clinical Pharmacology and Therapeutics, 67, 283–291. doi:10.1067/mcp.2000.104788
   PubMed Web of Science ®Google Scholar
• Hewer, W., Rost, W., & Gattaz, W. F. (1995). Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. European Archives of Psychiatry and Clinical Neuroscience, 246, 1–6. doi:10.1007/BF02191808
   PubMed Web of Science ®Google Scholar
• Ho, J. M., Gomes, T., Straus, S. E., Austin, P. C., Mamdani, M., & Juurlink, D. N. (2014). Adverse cardiac events in older patients receiving venlafaxine: A population-based study. The Journal of Clinical Psychiatry, 75, e552–e558. doi:10.4088/JCP.13m08508
   PubMed Web of Science ®Google Scholar
• Hohnloser, S. H., Klingenheben, T., & Singh, B. N. (1994). Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Annals of Internal Medicine, 121, 529–535. doi:10.7326/0003-4819-121-7-199410010-00009
   PubMed Web of Science ®Google Scholar
• Howell, C., Wilson, A. D., & Waring, W. S. (2007). Cardiovascular toxicity due to venlafaxine poisoning in adults: A review of 235 consecutive cases. British Journal of Clinical Pharmacology, 64, 192–197. doi:10.1111/j.1365-2125.2007.02849.x
   PubMed Web of Science ®Google Scholar
• Jiang, W. & Davidson, J. R. (2005). Antidepressant therapy in patients with ischemic heart disease. American Heart Journal, 150, 871–881. doi:10.1016/j.ahj.2005.01.041
   PubMed Web of Science ®Google Scholar
• Kaar, J. L., Luberto, C. M., Campbell, K. A., & Huffman, J. C. (2017). Sleep, health behaviors, and behavioral interventions: Reducing the risk of cardiovascular disease in adults. The World Journal of Cardiology, 9, 396–406. doi:10.4330/wjc.v9.i5.396
   PubMed Web of Science ®Google Scholar
• Kaplan, N. M. (2004). The place of diuretics in preventing cardiovascular events. Journal Of Human Hypertension, 18 Suppl 2, S29–S32.
   PubMed Web of Science ®Google Scholar
• Keller, T. T., Squizzato, A., & Middeldorp, S. (2007). Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database of Systematic Reviews, CD005158.
   PubMed Web of Science ®Google Scholar
• Kim, J. M., Bae, K. Y., Stewart, R., Jung, B. O., Kang, H. J., Kim, S. W. et al. (2015). Escitalopram treatment for depressive disorder following acute coronary syndrome: A 24-week double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry, 76, 62–68.
   PubMed Web of Science ®Google Scholar
• Kleiger, R. E., Miller, J. P., Bigger, J. T., Jr., & Moss, A. J. (1987). Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. American Journal of Cardiology, 59, 256–262. doi:10.1016/0002-9149(87)90795-8
   PubMed Web of Science ®Google Scholar
• Koide, T., Wakabayashi, T., Matsuda, T., Horiike, S., & Watanabe, K. (2010). Hyponatremia associated with paroxetine induced by sodium-restricted diet and hypotonic saline. Pharmacy World & Science, 32, 19–21. doi:10.1007/s11096-009-9353-5
   PubMedGoogle Scholar
• Konig, F., Hafele, M., Hauger, B., Loble, M., Wossner, S., & Wolfersdorf, M. (1996). Bradycardia after beginning therapy with metoprolol and paroxetine. Psychiatrische Praxis, 23, 244–245.
   PubMed Web of Science ®Google Scholar
• Krishnan, K. R., Doraiswamy, P. M., & Clary, C. M. (2001). Clinical and treatment response characteristics of late-life depression associated with vascular disease: A pooled analysis of two multicenter trials with sertraline. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 25, 347–361. doi:10.1016/S0278-5846(00)00168-8
   PubMed Web of Science ®Google Scholar
• Kubota, T. & Miyata, A. (2006). Syndrome of inappropriate secretion of antidiuretic hormone associated with paroxetine. The Journal of Anesthesia, 20, 126–128. doi:10.1007/s00540-005-0381-6
   PubMedGoogle Scholar
• Laird, L. K., Lydiard, R. B., Morton, W. A., Steele, T. E., Kellner, C., Thompson, N. M., & Ballenger, J. C. (1993). Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. The Journal of Clinical Psychiatry, 54, 224–228.
   PubMed Web of Science ®Google Scholar
• Larsen, F., Priskorn, M., & Overo, K. F. (2001). Lack of citalopram effect on oral digoxin pharmacokinetics. Journal of Clinical Pharmacology, 41, 340–346. doi:10.1177/00912700122010041
   PubMed Web of Science ®Google Scholar
• Leibovitz, A., Bilchinsky, T., Gil, I., & Habot, B. (1998). Elevated serum digoxin level associated with coadministered fluoxetine. Archives of Internal Medicine, 158, 1152–1153. doi:10.1001/archinte.158.10.1152
   PubMedGoogle Scholar
• Leonard, C. E., Bilker, W. B., Newcomb, C., Kimmel, S. E., & Hennessy, S. (2011). Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiology and Drug Safety, 20, 903–913. doi:10.1002/pds.2181
   PubMed Web of Science ®Google Scholar
• Letsas, K., Korantzopoulos, P., Pappas, L., Evangelou, D., Efremidis, M., & Kardaras, F. (2006). QT interval prolongation associated with venlafaxine administration. The International Journal of Cardiology, 109, 116–117. doi:10.1016/j.ijcard.2005.03.065
   PubMed Web of Science ®Google Scholar
• Li, Z., Li, Y., Chen, L., Chen, P., & Hu, Y. (2015). Prevalence of depression in patients with hypertension: A systematic review and meta-analysis. Medicine (Baltimore), 94, e1317.
   PubMed Web of Science ®Google Scholar
• Lichtman, J. H., Bigger, J. T., Jr., Blumenthal, J. A., Frasure-Smith, N., Kaufmann, P. G., Lesperance, F. et al. (2008). Depression and coronary heart disease: recommendations for screening, referral, and treatment: A science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation, 118, 1768–1775.
   PubMed Web of Science ®Google Scholar
• Limke, K. K., Shelton, A. R., & Elliott, E. S. (2002). Fluvoxamine interaction with warfarin. The Annals of Pharmacotherapy, 36, 1890–1892. doi:10.1345/aph.1C112
   PubMed Web of Science ®Google Scholar
• LoVecchio, F., Riley, B., Pizon, A., & Brown, M. (2008). Outcomes after isolated mirtazapine (Remeron) supratherapeutic ingestions. The Journal of Emergency Medicine, 34, 77–78. doi:10.1016/j.jemermed.2007.03.006
   PubMed Web of Science ®Google Scholar
• May, H. T., Bair, T. L., Reiss-Brennan, B., Knight, S., Anderson, J. L., Horne, B. D., & Muhlestein, J. B. (2017a). The association of antidepressant and statin use with death and incident cardiovascular disease varies by depression severity. Psychology, Health & Medicine, 22, 919–931. doi:10.1080/13548506.2017.1281975
   PubMed Web of Science ®Google Scholar
• May, H. T., Horne, B. D., Carlquist, J. F., Sheng, X., Joy, E., & Catinella, A. P. (2009). Depression after coronary artery disease is associated with heart failure. Journal of the American College of Cardiology, 53, 1440–1447.
   PubMed Web of Science ®Google Scholar
• May, H. T., Horne, B. D., Knight, S., Knowlton, K. U., Bair, T. L., Lappe, D. L., … Muhlestein, J. B. (2017b). The association of depression at any time to the risk of death following coronary artery disease diagnosis. European Heart Journal - Quality of Care & Clinical Outcomes, 3, 296–302. doi:10.1093/ehjqcco/qcx017
   PubMed Web of Science ®Google Scholar
• Mbaya, P., Alam, F., Ashim, S., & Bennett, D. (2007). Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Human Psychopharmacology, 22, 129–133. doi:10.1002/hup.834
   PubMed Web of Science ®Google Scholar
• McCollum, D. L., Greene, J. L., & McGuire, D. K. (2004). Severe sinus bradycardia after initiation of bupropion therapy: A probable drug-drug interaction with metoprolol. Cardiovascular Drugs and Therapy, 18, 329–330. doi:10.1023/B:CARD.0000041254.15807.98
   PubMed Web of Science ®Google Scholar
• Medvedev, V. E. (2017). Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: Results of the national multicenter observational study PULSE. Neuropsychiatric Disease and Treatment, 13, 1141–1151. doi:10.2147/NDT.S129793
   PubMed Web of Science ®Google Scholar
• Meng, L., Chen, D., Yang, Y., Zheng, Y., & Hui, R. (2012). Depression increases the risk of hypertension incidence: A meta-analysis of prospective cohort studies. Journal of Hypertension, 30, 842–851. doi:10.1097/HJH.0b013e32835080b7
   PubMed Web of Science ®Google Scholar
• Mermi, O. & Atmaca, M. (2016). Duloxetine-induced hypertension: A case report. Turkish journal of psychiatry, 27, 67–69.
   Google Scholar
• Molnari, J. C., Hassan, H. E., Moeller, B. M., & Myers, A. L. (2011). Drug interaction study between bupropion and ticlopidine in male CF-1 mice. Biological and Pharmaceutical Bulletin, 34, 447–451. doi:JST.JSTAGE/bpb/34.447
   PubMed Web of Science ®Google Scholar
• Mori, M., Koide, T., Imanishi, Y., Matsui, Y., & Matsuda, T. (2014). Duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics. Indian Journal of Pharmacology, 46, 657–659. doi:10.4103/0253-7613.144947
   PubMed Web of Science ®Google Scholar
• Olfson, M. & Marcus, S. C. (2009). National patterns in antidepressant medication treatment. Archives of General Psychiatry, 66, 848–856. doi:10.1001/archgenpsychiatry.2009.81
   PubMed Web of Science ®Google Scholar
• Onalan, O., Cumurcu, B. E., & Bekar, L. (2008). Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clinic Proceedings, 83, 595–599.
   PubMed Web of Science ®Google Scholar
• Orsolini, L., Tomasetti, C., Valchera, A., Iasevoli, F., Buonaguro, E. F., Fornaro, M., … Berardis, D. (2017). Current and future perspectives on the major depressive disorder: Focus on the new multimodal antidepressant vortioxetine. CNS & Neurological Disorders - Drug Targets, 16, 65–92. doi:10.2174/1871527315666161025140111
   PubMed Web of Science ®Google Scholar
• Parker, R. B. & Soberman, J. E. (2011). Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy, 31, 630–641. doi:10.1592/phco.31.7.630
   PubMed Web of Science ®Google Scholar
• Paz-Filho, G., Licinio, J., & Wong, M. L. (2010). Pathophysiological basis of cardiovascular disease and depression: A chicken-and-egg dilemma. Revista Brasileira de Psiquiatria, 32, 181–191. doi:S1516-44462010000200015
   PubMed Web of Science ®Google Scholar
• Penninx, B. W. (2017). Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms. Neuroscience and Biobehavioral Reviews, 74, 277–286. doi:10.1016/j.neubiorev.2016.07.003
   PubMed Web of Science ®Google Scholar
• Perucca, E., Gatti, G., & Spina, E. (1994). Clinical pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics, 27, 175–190. doi:10.2165/00003088-199427030-00002
   PubMed Web of Science ®Google Scholar
• Preskorn, S. H., Greenblatt, D. J., Flockhart, D., Luo, Y., Perloff, E. S., Harmatz, J. S., … Burt, T. (2007). Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. Journal of Clinical Psychopharmacology, 27, 28–34. doi:10.1097/00004714-200702000-00005
   PubMed Web of Science ®Google Scholar
• Priskorn, M., Sidhu, J. S., Larsen, F., Davis, J. D., Khan, A. Z., & Rolan, P. E. (1997). Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. British Journal of Clinical Pharmacology, 44, 199–202.
   PubMed Web of Science ®Google Scholar
• Rajpurohit, N., Aryal, S. R., Khan, M. A., Stys, A. T., & Stys, T. P. (2014). Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: A case of severe drug interaction. South Dakota Journal of Medicine, 67, 137–139.
   PubMedGoogle Scholar
• Rapeport, W. G., Coates, P. E., Dewland, P. M., & Forster, P. L. (1996). Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. The Journal of Clinical Psychiatry, 57, 16–19.
   PubMed Web of Science ®Google Scholar
• Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2017). High-dose citalopram and escitalopram and the risk of out-of-hospital death. The Journal of Clinical Psychiatry, 78, 190–195. doi:10.4088/JCP.15m10324
   PubMed Web of Science ®Google Scholar
• Renshaw, P. F., Parsegian, A., Yang, C. K., Novero, A., Yoon, S. J., Lyoo, I. K., … Carlezon, W. A., Jr. (2009). Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats. Pharmacology Biochemistry & Behavior, 92, 88–92. doi:10.1016/j.pbb.2008.10.017
   PubMed Web of Science ®Google Scholar
• Reznik, I., Rosen, Y., & Rosen, B. (1999). An acute ischaemic event associated with the use of venlafaxine: A case report and proposed pathophysiological mechanisms. Journal of Psychopharmacology, 13, 193–195. doi:10.1177/026988119901300212
   PubMed Web of Science ®Google Scholar
• Roos, J. C. (1983). Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine. British Journal of Clinical Pharmacology, 15, 439S–445S. doi:10.1111/j.1365-2125.1983.tb02135.x
   PubMed Web of Science ®Google Scholar
• Roose, S. P., Dalack, G. W., Glassman, A. H., Woodring, S., Walsh, B. T., & Giardina, E. G. (1991). Cardiovascular effects of bupropion in depressed patients with heart disease. The American Journal of Psychiatry, 148, 512–516. doi:10.1176/ajp.148.4.512
   PubMed Web of Science ®Google Scholar
• Roose, S. P., Glassman, A. H., Attia, E., Woodring, S., Giardina, E. G., & Bigger, J. T., Jr. (1998a). Cardiovascular effects of fluoxetine in depressed patients with heart disease. The American Journal of Psychiatry, 155, 660–665. doi:10.1176/ajp.155.5.660
   PubMed Web of Science ®Google Scholar
• Roose, S. P., Laghrissi-Thode, F., Kennedy, J. S., Nelson, J. C., Bigger, J. T., Jr., Pollock, B. G., … Gergel, I. (1998b). Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. The Journal of the American Medical Association, 279, 287–291. doi:10.1001/jama.279.4.287
   PubMed Web of Science ®Google Scholar
• Rutledge, T., Reis, V. A., Linke, S. E., Greenberg, B. H., & Mills, P. J. (2006). Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. Journal of the American College of Cardiology, 48, 1527–1537. doi:10.1016/j.jacc.2006.06.055
   PubMed Web of Science ®Google Scholar
• Santangelo, A., Testai, M., Barbagallo, P., Crisafulli, C., Grasso, S., Manuele, S. et al. (2009). Use of specific serotonin reuptake inhibitors (SSRIs) (Sertraline or Citalopram) in the treatment of depression reduces the cardiovascular risk in the elderly: Evidence from a Sicilian population >80 years recovered in the assisted sanitary residences (RSA). Archives of Gerontology and Geriatrics, 48, 350–352.
   PubMed Web of Science ®Google Scholar
• Serebruany, V. L., Glassman, A. H., Malinin, A. I., Nemeroff, C. B., Musselman, D. L., van Zyl, L. T., … O'Connor, C. M. (2003). Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation, 108, 939–944. doi:10.1161/01.CIR.0000085163.21752.0A
   PubMed Web of Science ®Google Scholar
• Servier Laboratories. (2015). Summary of product characteristics: Valdoxan. Retrieved from https://www.medicines.org.uk/emc/medicine/21830
   Google Scholar
• Shah, S. U., Anjum, S., & Littler, W. A. (2004a). Use of diuretics in cardiovascular disease: (2) hypertension. Postgraduate Medical Journal, 80, 271–276. doi:10.1136/pgmj.2003.010843
   PubMed Web of Science ®Google Scholar
• Shah, S. U., Anjum, S., & Littler, W. A. (2004b). Use of diuretics in cardiovascular diseases: (1) heart failure. Postgrad. Med. J, 80, 201–205.
   PubMed Web of Science ®Google Scholar
• Shah, S. U., Anjum, S., & Littler, W. A. (2004). Use of diuretics in cardiovascular diseases: (1) heart failure. Postgraduate Medical Journal, 80, 201–205. doi:10.1136/pgmj.2003.010835
   PubMed Web of Science ®Google Scholar
• Shao, H., Mohammed, M. U., Thomas, N., Babazadeh, S., Yang, S., Shi, Q., & Shi, L. (2017). Evaluating excessive burden of depression on health status and health care utilization among patients with hypertension in a nationally representative sample from the medial expenditure panel survey (MEPS 2012). Journal of Nervous and Mental Disease, 205, 397–404. doi:10.1097/NMD.0000000000000618
   PubMed Web of Science ®Google Scholar
• Shapiro, P. A., Lesperance, F., Frasure-Smith, N., O'Connor, C. M., Baker, B., Jiang, J. W., … Glassman, A. H. (1999). An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline anti-depressant heart attack trial. American Heart Journal, 137, 1100–1106. doi:10.1016/S0002-8703(99)70369-8
   PubMed Web of Science ®Google Scholar
• Shin, D., Oh, Y. H., Eom, C. S., & Park, S. M. (2014). Use of selective serotonin reuptake inhibitors and risk of stroke: A systematic review and meta-analysis. The Journal of the Neurological Sciences, 261, 686–695. doi:10.1007/s00415-014-7251-9
   Google Scholar
• Spindelegger, C. J., Papageorgiou, K., Grohmann, R., Engel, R., Greil, W., Konstantinidis, A., … Kasper, S. (2014). Cardiovascular adverse reactions during antidepressant treatment: A drug surveillance report of German-speaking countries between 1993 and 2010 11. International Journal of Neuropsychopharmacology, 18, 1–9. doi:10.1093/ijnp/pyu080
   Web of Science ®Google Scholar
• Squizzato, A., Keller, T., Romualdi, E., & Middeldorp, S. (2011). Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database of Systematic Reviews, CD005158. doi:10.1002/14651858.CD005158.pub3
   PubMed Web of Science ®Google Scholar
• Stefanska, E., Wendolowicz, A., Cwalina, U., Konarzewska, B., Waszkiewicz, N., & Ostrowska, L. (2016). Eating habits and the risk of cardiovascular disease in patients with recurrent depressive disorders. Psychiatria Polska, 50, 1119–1133. doi:10.12740/PP/62682
   PubMed Web of Science ®Google Scholar
• Stevens, D. L. (2008). Duloxetine-associated tachycardia. Annals of Pharmacotherapy, 42, 1511–1513. 10.1345/aph.1L108
   PubMed Web of Science ®Google Scholar
• Stout, S. M., Nielsen, J., Bleske, B. E., Shea, M., Brook, R., Kerber, K., & Welage, L. S. (2010). The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. Journal of Cardiovascular Pharmacology and Therapeutics, 15, 373–379. doi:10.1177/1074248410372926
   PubMed Web of Science ®Google Scholar
• Stout, S. M., Nielsen, J., Welage, L. S., Shea, M., Brook, R., Kerber, K. (2011). Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. Journal of Clinical Pharmacology, 51, 389–396. doi:10.1177/0091270010365559
   PubMed Web of Science ®Google Scholar
• Straneva-Meuse, P. A., Light, K. C., Allen, M. T., Golding, M., & Girdler, S. S. (2004). Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients. The Journal of Affective Disorders, 79, 51–61.
   PubMed Web of Science ®Google Scholar
• Strik, J. J., Honig, A., Lousberg, R., Lousberg, A. H., Cheriex, E. C., Tuynman-Qua, H. G., & Bleske, B. E. (2000). Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: Findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine, 62, 783–789. doi:10.1097/00006842-200011000-00007
   PubMed Web of Science ®Google Scholar
• Swenson, J. R. (2004). Quality of life in patients with coronary artery disease and the impact of depression. Current Psychiatry Reports, 6, 438–445. doi:10.1007/s11920-004-0008-x
   PubMedGoogle Scholar
• Swenson, J. R., Doucette, S., & Fergusson, D. (2006). Adverse cardiovascular events in antidepressant trials involving high-risk patients: A systematic review of randomized trials. The Canadian Journal of Psychiatry, 51, 923–929. doi:10.1177/070674370605101408
   PubMed Web of Science ®Google Scholar
• Tatonetti, N. P., Denny, J. C., Murphy, S. N., Fernald, G. H., Krishnan, G., Castro, V., … Altman, R. B. (2011). Detecting drug interactions from adverse-event reports: Interaction between paroxetine and pravastatin increases blood glucose levels. Clinical Pharmacology & Therapeutics, 90, 133–142. doi:10.1038/clpt.2011.83
   PubMed Web of Science ®Google Scholar
• Terhardt, J., Lederbogen, F., Feuerhack, A., Hamann-Weber, B., Gilles, M., Schilling, C. et al. (2013). Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine. Clinical Neuropharmacology, 36, 198–202.
   PubMed Web of Science ®Google Scholar
• Terpening, C. (2009). An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. The Journal of the American Board of Family Medicine, 22, 51–56. doi:10.3122/jabfm.2009.01.070282
   PubMed Web of Science ®Google Scholar
• Thase, M. E. (1998). Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients. The Journal of Clinical Psychiatry, 59, 502–508.
   PubMed Web of Science ®Google Scholar
• Thase, M. E., Larsen, K. G., Reines, E., & Kennedy, S. H. (2013). The cardiovascular safety profile of escitalopram. European Neuropsychopharmacology, 23, 1391–1400. doi:10.1016/j.euroneuro.2013.05.011
   PubMed Web of Science ®Google Scholar
• Thase, M. E., Tran, P. V., Wiltse, C., Pangallo, B. A., Mallinckrodt, C., & Detke, M. J. (2005). Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. Journal of Clinical Psychopharmacology, 25, 132–140. doi:00004714-200504000-00005
   PubMed Web of Science ®Google Scholar
• Turnheim, K. (2003). When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Experimental Gerontology, 38, 843–853. doi:S0531556503001335
   PubMed Web of Science ®Google Scholar
• Turpeinen, M., Tolonen, A., Uusitalo, J., Jalonen, J., Pelkonen, O., & Laine, K. (2005). Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clinical Pharmacology & Therapeutics, 77, 553–559.
   PubMed Web of Science ®Google Scholar
• van Zyl, L. T., Lesperance, F., Frasure-Smith, N., Malinin, A. I., Atar, D., Laliberte, M. A., & Serebruany, V. L. (2009). Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. The Journal of Thrombosis and Thrombolysis, 27, 48–56. doi:10.1007/s11239-007-0189-3
   PubMed Web of Science ®Google Scholar
• Vanhoutte, P. M. & Gao, Y. (2013). Beta blockers, nitric oxide, and cardiovascular disease. The Current Opinion Journals, 13, 265–273. doi:10.1016/j.coph.2012.12.002
   PubMed Web of Science ®Google Scholar
• Vassallo, P. & Trohman, R. G. (2007). Prescribing amiodarone: An evidence-based review of clinical indications. The Journal of the American Medical Association, 298, 1312–1322. doi:10.1001/jama.298.11.1312
   PubMed Web of Science ®Google Scholar
• Waring, W. S., Rhee, J. Y., Bateman, D. N., Leggett, G. E., & Jamie, H. (2008). Impaired heart rate variability and altered cardiac sympathovagal balance after antidepressant overdose. The European Journal of Pharmacology, 64, 1037–1041. doi:10.1007/s00228-008-0505-7
   Web of Science ®Google Scholar
• Weber, M. A. (2005). The role of the new beta-blockers in treating cardiovascular disease. American Journal of Hypertension, 18, 169S–176S.
   PubMed Web of Science ®Google Scholar
• Wenger, T. L. & Stern, W. C. (1983). The cardiovascular profile of bupropion. The Journal of Clinical Psychiatry, 44, 176–182.
   PubMed Web of Science ®Google Scholar
• Wernicke, J., Lledo, A., Raskin, J., Kajdasz, D. K., & Wang, F. (2007). An evaluation of the cardiovascular safety profile of duloxetine: Findings from 42 placebo-controlled studies. Drug Safety, 30, 437–455. doi:10.2165/00002018-200730050-00007
   PubMed Web of Science ®Google Scholar
• Weston, C. & Rao, U. (2003). Antiplatelet drugs in cardiovascular diseases. International Journal of Clinical Practice, 57, 898–905.
   PubMed Web of Science ®Google Scholar
• Yap, K. B. & Low, S. T. (1999). Interaction of fluvoxamine with warfarin in an elderly woman. Singapore Medical Journal, 40, 480–482.
   PubMedGoogle Scholar
• Yeh, T. C., Kao, L. C., Tzeng, N. S., Kuo, T. B., Huang, S. Y., Chang, C. C., & Chang, H. A. (2016). Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA). Progress in Neuro-Psychopharmacology & Biological Psychiatry, 64, 60–67. doi:10.1016/j.pnpbp.2015.07.007
   PubMed Web of Science ®Google Scholar
• Yeragani, V. K., Pesce, V., Jayaraman, A., & Roose, S. (2002). Major depression with ischemic heart disease: Effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry, 52, 418–429. doi:10.1016/S0006-3223(02)01394-X
   PubMed Web of Science ®Google Scholar
• Ziegler, M. G. & Wilner, K. D. (1996). Sertraline does not alter the beta-adrenergic blocking activity of atenolol in healthy male volunteers. The Journal of Clinical Psychiatry, 57, 12–15.
   PubMed Web of Science ®Google Scholar
• Zimmer, B., Kant, R., Zeiler, D., & Brilmyer, M. (1997). Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders. The International Journal of Psychiatry in Medicine, 27, 353–364. doi:10.2190/UDRD-99CB-T6KH-EDKP
   PubMed Web of Science ®Google Scholar
• Zivin, K., Pfeiffer, P. N., Bohnert, A. S., Ganoczy, D., Blow, F. C., Nallamothu, B. K., & Kales, H. C. (2013). Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. The American Journal of Psychiatry, 170, 642–650. doi:10.1176/appi.ajp.2013.12030408
   PubMed Web of Science ®Google Scholar